I have more than 19 years’ experience in the pharmaceutical medical industry, particularly in the fields of diabetes and obesity, where I have an extensive global network. I thrive on bringing science, business and leadership together so we can reach more patients and improve the lives of people with health issues.
In my current role as Vice President Global Medical Affairs for Cardiovascular, Renal and Metabolism, I lead the team to bring the data from AstraZeneca’s medicines to practising clinicians, so they can improve patient care. We listen to what doctors, nurses and pharmacists need to better serve their patients, so we can develop our medicines accordingly. It’s a bi-directional flow; on the one hand, we make clinical sense of the data the company produces so it can be used by health-care providers, and, on the other, we bring the clinical reality back to the company so our medicines can target what is needed.
My drive comes from making sure the right data, information, and evidence is developed and communicated in the right way, so that people receive the correct treatment.
It was by serendipity, however, that I ended up in the pharmaceutical industry. After working as a practising physician in Argentina, I came to Denmark to complete my residency, but needed to improve my Danish. I got a job as an international medical adviser at a large multi-national pharmaceutical company, and loved every minute. I enjoyed finding out about the science behind diabetes and obesity, and being able to develop data that can change the lives of millions of patients. It really fascinated me, and continues to do so, which is why I am still in the industry almost 20 years later.
Making sure the right data, information, and evidence is developed and communicated in the right way, so that people receive the correct treatment – that’s what drives me.
Throughout my career, I have managed teams of medical professionals involved in developing and marketing medicines for the treatment of growth disorders, haemophilia, hormone-replacement therapy, obesity and diabetes.
I love bringing out the best in people and building teams, so we can achieve our goals of giving the best patient care we can.
I am passionate about good leadership. I love bringing out the best in people and building teams, so we can achieve our goals of giving the best patient care we can. It gives me great satisfaction when I see people I have nurtured holding senior leadership roles in different companies.
I am very proud of the CaReMe (cardio, renal and metabolic) approach we are developing at AstraZeneca, where we are looking at more holistic ways to treat patients
I am very proud of the CaReMe (cardio, renal and metabolic) approach we are developing at AstraZeneca, looking at more holistic ways to treat patients. We are finding that medicines used for one condition can be evaluated to treat another or address underlying risks for co-morbidities. Healthcare professionals should be looking at patients in this way too – and we want to help facilitate and drive changes, so treatment comes from a multi-speciality group. My team came up with the CaReMe acronym, and we’ve been heavily involved in making it a key strategic approach in the company.
In my time working in the US, I built and developed a footprint for the company that allowed us to communicate our data in the right way with a very diverse range of stakeholders – which is quite a challenge in the US market, where the key decision-makers vary depending which state or city you are in. I redeployed my group of medical scientific liaison teams to take the information to stakeholders in ways that were appropriate to their individual requirements.
Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes.
Verge D, Lopez X. Current Diabetes Reviews 2010; 6 (4): 191-200
Seguridad de los análogos de insulina: qué evaluar, cómo hacerlo, y cómo interpretar los resultados.
Hernández A, Solá E, García K, Verge D. EndocrinolNutr.2010.doi:10.1016/j.endonu.2010.05.001
Innovative Solutions for Diabetes Therapy.
Verge D. Diabetes Research and Clinical Practice 2006; 74 (S2): S148-151.
Eye to Eye (The Role of the Medical Marketer).
Verge D. Pharmaceutical Marketing Europe 2006, Winter issue.
Insulinotherapie: innovations dans les molecules et les voies d’administration.
Verge D. Medecine/Sciences 2004; 20 (11): 986-98.
Insulin aspart: promising early results borne out in clinical practice.
Heller S, Kurtzhals P, Verge D, Lindholm A. Expert Opin Pharmacother 2002;3(2):183-195.
NK Cells and their Role in Transplantation.
Verge D. Nexo Rev. Hosp. Ital. Bs. As.; 15:2, September 1995.
Liver Xenotransplantation (experimental model).
Argibay P, Verge D, Sun Hai P. 8th Argentine Congress of Hepatology, July 1994.
Extracorporeal Auxiliary Liver: Bridge to Transplantation in Fulminant Hepatitis.
Argibay P, Verge D, Sun Hai P. 8th Argentine, Congress of Hepatology, July 1994.
Removal of Antibodies as a Previous Step to Xenotransplantation.
Argibay P, Verge D, Sun Hai P. VII Transplant Cytology, Immunology and Histology Workshop, November 1993.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.